Fesoterodine
- Generic Name
- Fesoterodine
- Brand Names
- Toviaz
- Drug Type
- Small Molecule
- Chemical Formula
- C26H37NO3
- CAS Number
- 286930-02-7
- Unique Ingredient Identifier
- 621G617227
- Background
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
- Indication
适用于治疗急迫性尿失禁和膀胱过度活动综合征患者的尿频、尿急、尿失禁或所有这些症状组合。
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Fall Prevention in Older Adults With OAB
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 74
- Registration Number
- NCT03946124
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 805
- Registration Number
- NCT03572231
- Locations
- 🇰🇷
Site KR410008, Daejeon, Korea, Republic of
🇰🇷Site KR410009, Incheon, Korea, Republic of
🇰🇷Site KR410005, Kangam, Korea, Republic of
Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 15
- Registration Number
- NCT02676154
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Stéphane Bolduc
- Target Recruit Count
- 26
- Registration Number
- NCT02614482
- Locations
- 🇨🇦
CHU de Québec-Université Laval, Québec City, Quebec, Canada
Fesoterodine on Urgency Episodes in Parkinson's Disease Population
- Conditions
- Interventions
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT02385500
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Stéphane Bolduc
- Target Recruit Count
- 62
- Registration Number
- NCT02327936
Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Mount Sinai Hospital, Canada
- Target Recruit Count
- 4
- Registration Number
- NCT02262936
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 3
- Registration Number
- NCT01661166
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 60
- Registration Number
- NCT01595152
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇱Belinson, Petach Tikva, Israel
🇮🇱Asaf harofeh, Tel Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.